Eli Lilly Acquires CrossBridge Bio to Boost Dual-Payload Antibody Innovation
In a significant move to enhance its capabilities in antibody-drug conjugates, Eli Lilly and Company has reached an agreement to acquire CrossBridge Bio, Inc. This Houston-based biotechnology startup, founded in 2023, is at the forefront of developing innovative dual-payload antibody-drug conjugates (ADCs).
Eli Lilly’s Acquisition of CrossBridge Bio
The acquisition will allow Lilly to integrate CrossBridge’s cutting-edge technology into its portfolio, aiming to advance the next generation of ADCs that have the potential to significantly impact cancer treatment.
Innovative Technology from CrossBridge Bio
CrossBridge Bio was established based on research by Dr. Kyoji Tsuchikama at the University of Texas Health Science Center at Houston (UTHealth Houston). The company’s flagship product, CBB-120, targets TROP2 and utilizes a dual-payload mechanism combining a Topo1 inhibitor and an ATR inhibitor. This innovative approach is expected to enhance therapeutic outcomes by providing more durable patient responses and mitigating resistance mechanisms commonly seen with existing therapies.
Future Development Plans
The U.S. Food and Drug Administration (FDA) is anticipated to receive an Investigational New Drug (IND) application for CBB-120 in 2026. The potential for this technology is coupled with Lilly’s expertise in developing patient-focused therapeutics.
Financial Aspects of the Deal
The terms of the acquisition include a payment structure worth up to $300 million, which encompasses both an upfront payment and additional remuneration upon reaching specified development milestones.
Support and Advisors
CrossBridge Bio has garnered support from various investors, including the Texas Medical Center (TMC) Venture Fund and CE-Ventures. Additionally, Alexandria Venture Investments, Portal Innovations, and Linden Lake Labs have contributed to the firm’s funding. The company is advised by Cooley LLP as legal counsel and Zwick Advisory, LLC as a strategic advisor.
Impact on Cancer Treatment
Dr. Michael Torres, Co-Founder and CEO of CrossBridge Bio, expressed optimism about the partnership with Lilly. He emphasized that their dual-payload ADC platform is uniquely positioned to revolutionize oncology practices, particularly for patients facing limited treatment options.
- Acquired Company: CrossBridge Bio, Inc.
- Acquiring Company: Eli Lilly and Company
- Founding Year: 2023
- Lead Candidate: CBB-120
- Target: TROP2
- Key Technology: Dual-payload ADCs
- Expected IND Filing: 2026
- Acquisition Value: Up to $300 million
This acquisition signals a hopeful advancement in the fight against cancer, relying on innovative strategies to improve patient outcomes. As the partnership unfolds, the medical community will be closely monitoring the developments in dual-payload antibody-drug conjugate technology.
